| Brian De La Rosa, MD | |
|
2800 Main St, St. Vincents Medical Center, Bridgeport, CT 06606-4201 | |
| (203) 576-5177 | |
| Not Available |
| Full Name | Brian De La Rosa |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 29 Years |
| Location | 2800 Main St, Bridgeport, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235276197 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 040558 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Vincent's Medical Center | Bridgeport, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hartford Healthcare Medical Group Specialists Pllc | 3173866241 | 1138 |
News Archive
A new online database will empower researchers exploring how hair follicles and the surrounding skin develop, according to an article published recently in the journal Developmental Cell. The work is central to understanding the interactions between stem cells and their environment - or "niche cells" - during fetal development, and will specifically facilitate future attempts to make skin grafts with functional hair follicles or to regenerate lost hair in patients.
House lawmakers are considering several bills Thursday to make health care pricing more transparent, Modern Healthcare reports. The Energy and Commerce's health subcommittee "plans to take up a trio of bills aimed at increasing transparency and clarity in healthcare pricing, tackling an issue that has bedeviled the industry for decades and handcuffed efforts to turn everyday people into better purchasers of care."
Botox- (onabotulinum toxin-A) injections to the bladder are as effective as medication for treating urinary urgency incontinence in women, but the injection is twice as likely to completely resolve symptoms. These findings were published in the latest issue of The New England Journal of Medicine by a National Institutes of Health clinical trials network including Loyola University Chicago Stritch School of Medicine (SSOM).
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.
› Verified 5 days ago
| Entity Name | St. Vincent's Multispecialty Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043544489 PECOS PAC ID: 6204977218 Enrollment ID: O20100112000538 |
News Archive
A new online database will empower researchers exploring how hair follicles and the surrounding skin develop, according to an article published recently in the journal Developmental Cell. The work is central to understanding the interactions between stem cells and their environment - or "niche cells" - during fetal development, and will specifically facilitate future attempts to make skin grafts with functional hair follicles or to regenerate lost hair in patients.
House lawmakers are considering several bills Thursday to make health care pricing more transparent, Modern Healthcare reports. The Energy and Commerce's health subcommittee "plans to take up a trio of bills aimed at increasing transparency and clarity in healthcare pricing, tackling an issue that has bedeviled the industry for decades and handcuffed efforts to turn everyday people into better purchasers of care."
Botox- (onabotulinum toxin-A) injections to the bladder are as effective as medication for treating urinary urgency incontinence in women, but the injection is twice as likely to completely resolve symptoms. These findings were published in the latest issue of The New England Journal of Medicine by a National Institutes of Health clinical trials network including Loyola University Chicago Stritch School of Medicine (SSOM).
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.
› Verified 5 days ago
| Entity Name | Hartford Healthcare Medical Group Specialists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023584216 PECOS PAC ID: 3173866241 Enrollment ID: O20190514001441 |
News Archive
A new online database will empower researchers exploring how hair follicles and the surrounding skin develop, according to an article published recently in the journal Developmental Cell. The work is central to understanding the interactions between stem cells and their environment - or "niche cells" - during fetal development, and will specifically facilitate future attempts to make skin grafts with functional hair follicles or to regenerate lost hair in patients.
House lawmakers are considering several bills Thursday to make health care pricing more transparent, Modern Healthcare reports. The Energy and Commerce's health subcommittee "plans to take up a trio of bills aimed at increasing transparency and clarity in healthcare pricing, tackling an issue that has bedeviled the industry for decades and handcuffed efforts to turn everyday people into better purchasers of care."
Botox- (onabotulinum toxin-A) injections to the bladder are as effective as medication for treating urinary urgency incontinence in women, but the injection is twice as likely to completely resolve symptoms. These findings were published in the latest issue of The New England Journal of Medicine by a National Institutes of Health clinical trials network including Loyola University Chicago Stritch School of Medicine (SSOM).
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian De La Rosa, MD 2800 Main St, St. Vincents Medical Center, Bridgeport, CT 06606-4201 Ph: (203) 576-5177 | Brian De La Rosa, MD 2800 Main St, St. Vincents Medical Center, Bridgeport, CT 06606-4201 Ph: (203) 576-5177 |
News Archive
A new online database will empower researchers exploring how hair follicles and the surrounding skin develop, according to an article published recently in the journal Developmental Cell. The work is central to understanding the interactions between stem cells and their environment - or "niche cells" - during fetal development, and will specifically facilitate future attempts to make skin grafts with functional hair follicles or to regenerate lost hair in patients.
House lawmakers are considering several bills Thursday to make health care pricing more transparent, Modern Healthcare reports. The Energy and Commerce's health subcommittee "plans to take up a trio of bills aimed at increasing transparency and clarity in healthcare pricing, tackling an issue that has bedeviled the industry for decades and handcuffed efforts to turn everyday people into better purchasers of care."
Botox- (onabotulinum toxin-A) injections to the bladder are as effective as medication for treating urinary urgency incontinence in women, but the injection is twice as likely to completely resolve symptoms. These findings were published in the latest issue of The New England Journal of Medicine by a National Institutes of Health clinical trials network including Loyola University Chicago Stritch School of Medicine (SSOM).
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.
› Verified 5 days ago
Dr. Tanya Dhiren Shah, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 267 Grant St, Bridgeport, CT 06610 Phone: 203-384-3000 | |
Dr. Kevin J Sprague Ii, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2800 Main St, Emergency Department, Bridgeport, CT 06606 Phone: 203-576-5604 | |
Sally Syaunan Chao, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2800 Main St, St. Vincent Medical Center, Bridgeport, CT 06606 Phone: 203-576-5177 | |
Kimberly Anne Reade, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2800 Main St, Emergency Department, Bridgeport, CT 06606 Phone: 203-576-5604 | |
Dr. Jonathan Maisel, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 267 Grant St, Bridgeport, CT 06610 Phone: 203-384-4490 | |
Dr. Roland Martin Jermyn Iii, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 267 Grant St, Bridgeport, CT 06610 Phone: 203-384-3256 Fax: 203-384-4037 | |
Samantha Dane, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2800 Main St, St. Vincent Medical Center, Bridgeport, CT 06606 Phone: 203-576-5177 |